| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP, SGS |
| Suitable for: | Adult |
| State: | Powder |
| Purity: | 99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Name | Sonwu Supply Purity Sunitinib Malate Powder Sunitinib Malate |
| CAS NO. | 341031-54-7 |
| Molecular Formula | C22h27fn4o2.C4h6o5 |
| Purity | 99% |
| Appearance | White Powder |
| Certificate | ISO, SGS, GMP, HACCP |
| Assay Method | HPLC |
| Extraction Type | Solvent Extraction |
| Sample | Available |
| MOQ | 5g |
| Shelf life | 2 Years |
| Storage | Store in cool & dry place not freeze Keep away from strong light and heat |
Sunitinib is available in 12.5-, 25-, and 50-mg capsules fororal administration for the therapy of advanced RCC andGIST upon the failure of imatinib. The agent is a multikinaseinhibitor and has been shown to inhibit PDGF-R,VEGF-R, Kit, RET, and the colony-stimulating factor receptor(CSR-1R). The result of this spectrum of activity isa slowing of neoplasm progression and inhibition of angiogenesisboth of which are useful, RCC and GIST. The median TTP (time to neoplasm progression) was 27.3 weeks for sunitinib and 6.4 weeks with a median time of 24.1 weeks for sunitinib and 6 weeksfor placebo. The agent is well absorbed upon oral administration,and both the parent and major metabolite are highly(90%-95%) protein bound. Metabolism is mediated primarilyby CYP3A4 to give the N-desethyl derivative, which isthe major metabolite (23%-37%), equally active with theparent and undergoes further metabolism by CYP3A4. Theterminal elimination half-life for the parent and N-desethylderivative are 40 to 60 hours and 80 to 110 hours, respectively.Elimination occurs primarily via the feces. Commonadverse effects of sunitinib include fatigue, diarrhea, yellowskin discoloration, anorexia, nausea, and mucositis.Mild myelosuppression has been reported in patients with GIST including neutropenia, lymphopenia, thrombocytopenia,and anemia. There have been reports of cardiotoxicityincluding decreases in left ventricular ejectionfraction, which occurred in 11% of patients during a GISTstudy.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}